Soufflé Therapeutics raises $135M to advance RNA drug candidates
Soufflé Therapeutics has secured $135 million in venture funding. The Bob Langer-affiliated startup plans to use the money to develop at least three experimental oligonucleotide medicines.
Expanded Detail
EXPANDED:
Soufflé Therapeutics has obtained $135 million in venture backing. The startup, linked to Bob Langer, aims to move at least three experimental oligonucleotide medicines forward. The financing sits within RNA drug
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
Roche partners with Defand Therapeutics to develop molecular glue drugs · Drug development
City Therapeutics and Iambic line up Nasdaq IPOs · Drug development
Roche forms wider drug discovery partnership with Chinese startup Defand · Drug development
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Soufflé gets $135M for three RNA medicines.” Browse more stories.